suPAR and chronic kidney disease—a podocyte story

Pflugers Archiv European Journal of Physiology

Volumn 469, Issue 7-8, 2017, Pages 1017-1020

  Zeier, Martin ^a   Reiser, Jochen ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CKD; FSGS; Integrin; Podocyte; suPAR

Indexed keywords

BIOLOGICAL MARKER; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

CHRONIC KIDNEY FAILURE; DISEASE COURSE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NONHUMAN; OBSERVATIONAL STUDY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; ANIMAL; BLOOD; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INTEGRIN ALPHAVBETA3; PODOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RENAL INSUFFICIENCY, CHRONIC;

EID: 85021945154     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-017-2026-7     Document Type: Review

References (23)

1. Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM (2013) Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 96(7):649–656
2. Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak J (2015) Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep 5:13647
3. Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L (2014) Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol 25(8):1662–1668
4. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM (2014) A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6(256):256ra136
5. Guthoff M, Wagner R, Randrianarisoa E, Hatziagelaki E, Peter A, Häring HU, Fritsche A, Heyne N (2017) Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci Rep 7:40627
6. Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O'Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J (2017) Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med 23(1):100–106
7. Harita Y, Ishizuka K, Tanego A, Sugawara N, Chikamoto H, Akioka Y, Tsurumi H, Miura K, Gotoh Y, Tsujita M, Yamamoto T, Horike K, Takeda A, Oka A, Igarashi T, Hattori M (2014) Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol 29(9):1553–1560
8. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J (2015) Soluble urokinase receptor and chronic kidney disease. N Engl J Med 373(20):1916–1925
9. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One 11(7):e0158765
10. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687
11. Kriz W, Lemley KV (2015) A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 26(2):258–269
12. Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J (2013) Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther 20(2):226–229
13. Musetti C, Quaglia M, Cena T, Chiocchetti A, Monti S, Clemente N, Magnani C, Dianzani U, Stratta P (2015) Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis. J Nephrol 28(3):299–305
14. Nebuloni M, Zawada L, Ferri A, Tosoni A, Zerbi P, Resnati M, Poli G, Genovese L, Alfano M (2013) HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression. PLoS One 8(7):e70606
15. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123(10):754–762
16. Schenk H, Müller-Deile J, Schmitt R, Bräsen JH, Haller H, Schiffer M (2017) Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb. J Clin Apher
17. Schulz CA, Persson M, Christensson A, Hindy G, Almgren P, Nilsson PM, Melander O, Engström G, Orho-Melander M (2017) Soluble urokinase-type plasminogen activator receptor (suPAR) and impaired kidney function in the population-based Malmö diet and cancer study. Kidney Int Rep 2(2):239–247
18. Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB, Nephrotic Syndrome Study Network (2015) A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87(3):564–574
19. Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhynov D (2015) Recurrent primary focal segmental glomerulosclerosis managed with intensified plasma exchange and concomitant monitoring of soluble urokinase-type plasminogen activator receptor-mediated podocyte β3-integrin activation. Transplantation 99(12):2593–2597
20. Thunø M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27(3):157–172
21. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14(1):55–63
22. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960
23. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, JL MM, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J, PodoNet and FSGS CT Study Consortia (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23(12):2051–2059